Bacillus anthracis cell surface carbohydrates

炭疽芽孢杆菌细胞表面碳水化合物

基本信息

  • 批准号:
    6673663
  • 负责人:
  • 金额:
    $ 29.44万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-09-30 至 2005-09-29
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The bioterrorist threat with regard to Bacillus anthracis requires the development of improved vaccines, diagnostic, and therapeutic agents. Bacterial cell surface carbohydrates have been utilized for all three of these purposes, however, little is known about the B. anthracis cell wall carbohydrates. B. anthracis produces a capsule consisting of poly-g-glutamic acid, rather than a polysaccharide. However, recent work has shown that there are important carbohydrate components in both the vegetative and spore forms of B.anthracis. The vegetative cell wall contains a polysaccharide that is linked to peptidoglycan and serves to anchor the crystalline surface (S-layer) protein to the cell wall by binding with the SLH domain of the protein. This polysaccharide is referred to as the S-layer anchoring polysaccharide. The exosporium coat of the spore contains a major glycoprotein that is an immunodominant antigen of the spore. While the structure of the S-layer anchoring polysaccharide has not been determined, indirect data suggest that it has structural features that are specific to B. anthracis. There are no reports characterizing the carbohydrates of the exosporium glycoprotein. It is hypothesized that the B. anthracis cell wall contains carbohydrates (e.g. the S-layer anchoring polysaccharide and the exosporium glycoprotein) that are species and/or strain specific and are, therefore, candidates for the development of vaccines, diagnostic and therapeutic agents. The specific aims of this application are to (a.) determine if the S-layer anchoring polysaccharide and the exosporium carbohydrates have species specific structural features, (b.) determine if these same carbohydrates have strain specific structural features, and (c.) determine if the B. anthracis virulence plasmids, pX01 and pX02, encode for enzymes that structurally modify these carbohydrates. This work will be done by isolating and structurally characterizing these carbohydrates from several species of the B. cereus group, including B. anthracis var Ames, from several strains/isolates of B. anthracis, and from B.anthracis var Ames derivatives that have been differentially cured of pX01 or pX02, or of both plasmids. This work will be a collaborative effort between Dr. Russell Carlson at the Complex Carbohydrate Research Center at the University of Georgia, Dr. David Stephens at Emory University, and Dr. Conrad Quinn at the Centers for Disease Control.
描述(由申请人提供):与炭疽杆菌有关的生物恐怖威胁要求开发改进的疫苗、诊断和治疗试剂。细菌细胞表面的碳水化合物已经被用于所有这三个目的,然而,对炭疽杆菌细胞壁的碳水化合物知之甚少。炭疽杆菌产生的胶囊由多聚-g-谷氨酸组成,而不是多糖。然而,最近的研究表明,炭疽杆菌的营养形态和孢子形态中都有重要的碳水化合物成分。营养细胞壁含有一种与肽聚糖相连的多糖,通过与蛋白质的SLH结构域结合,将结晶表面(S层)蛋白质固定在细胞壁上。这种多糖被称为S层锚定多糖。孢子的外孢子层含有一种主要的糖蛋白,它是孢子的一种免疫优势抗原。虽然S层锚定多糖的结构尚未确定,但间接数据表明,它具有炭疽杆菌特有的结构特征。目前还没有关于外孢子菌糖蛋白的碳水化合物的报道。据推测,炭疽杆菌细胞壁含有碳水化合物(如S层锚定多糖和外孢子菌糖蛋白),这些碳水化合物是物种和/或菌株特有的,因此是疫苗、诊断和治疗药物开发的候选物质。本申请的具体目的是(a.)确定S层锚定多糖和外孢子菌碳水化合物是否具有物种特有的结构特征,(b.)确定这些碳水化合物是否具有菌株特有的结构特征,以及(c.)确定炭疽杆菌毒力质粒pX01和pX02是否编码对这些碳水化合物进行结构修饰的酶。这项工作将通过从蜡样芽孢杆菌组的几个物种,包括炭疽杆菌变种Ames,从炭疽杆菌的几个菌株/分离物,以及从已经用pX01或pX02或两个质粒不同治愈的炭疽杆菌变种Ames衍生物中分离和结构特征来完成。这项工作将是佐治亚大学复合碳水化合物研究中心的拉塞尔·卡尔森博士、埃默里大学的大卫·斯蒂芬斯博士和疾病控制中心的康拉德·奎因博士共同努力的结果。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RUSSELL W CARLSON其他文献

RUSSELL W CARLSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RUSSELL W CARLSON', 18)}}的其他基金

Rhizobial Lipopolysaccharides Essential for Infection
感染必需的根瘤菌脂多糖
  • 批准号:
    8008946
  • 财政年份:
    2010
  • 资助金额:
    $ 29.44万
  • 项目类别:
Biosynthesis & Function of a Bacillus anthracis-specific cell wall polysaccharide
生物合成
  • 批准号:
    7739417
  • 财政年份:
    2009
  • 资助金额:
    $ 29.44万
  • 项目类别:
Biosynthesis & Function of a Bacillus anthracis-specific cell wall polysaccharide
生物合成
  • 批准号:
    7860446
  • 财政年份:
    2009
  • 资助金额:
    $ 29.44万
  • 项目类别:
Bacillus anthracis cell surface carbohydrates
炭疽芽孢杆菌细胞表面碳水化合物
  • 批准号:
    6803538
  • 财政年份:
    2003
  • 资助金额:
    $ 29.44万
  • 项目类别:
STRUCTURAL DETERMINATION OF THE LPS FROM RHIZOBIUM
根瘤菌 LPS 的结构测定
  • 批准号:
    2179936
  • 财政年份:
    1988
  • 资助金额:
    $ 29.44万
  • 项目类别:
STRUCTURAL DETERMINATION OF THE LPS FROM RHIZOBIUM
根瘤菌 LPS 的结构测定
  • 批准号:
    2179937
  • 财政年份:
    1988
  • 资助金额:
    $ 29.44万
  • 项目类别:
STRUCTURAL DETERMINATION OF THE LPS FROM RHIZOBIUM
根瘤菌 LPS 的结构测定
  • 批准号:
    3296709
  • 财政年份:
    1988
  • 资助金额:
    $ 29.44万
  • 项目类别:
Rhizobial Lipopolysaccharides Essential for Infection
感染必需的根瘤菌脂多糖
  • 批准号:
    6624026
  • 财政年份:
    1988
  • 资助金额:
    $ 29.44万
  • 项目类别:
STRUCTURAL DETERMINATION OF THE LPS FROM RHIZOBIUM
根瘤菌 LPS 的结构测定
  • 批准号:
    2179935
  • 财政年份:
    1988
  • 资助金额:
    $ 29.44万
  • 项目类别:
STRUCTURAL DETERMINATION OF THE LPS FROM RHIZOBIUM
根瘤菌 LPS 的结构测定
  • 批准号:
    3296705
  • 财政年份:
    1988
  • 资助金额:
    $ 29.44万
  • 项目类别:

相似海外基金

Development of rapid detection method for drug-resistant bacteria in pulmonary MAC disease and search for new antibacterial agents
肺部MAC疾病耐药菌快速检测方法的建立及新型抗菌药物的寻找
  • 批准号:
    23K07930
  • 财政年份:
    2023
  • 资助金额:
    $ 29.44万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of novel antibacterial agents using crystal structure-based drug screening
利用基于晶体结构的药物筛选开发新型抗菌剂
  • 批准号:
    23K07918
  • 财政年份:
    2023
  • 资助金额:
    $ 29.44万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
ATP Synthase as an emerging target for the pre-clinical development of broad-spectrum antibacterial agents against drug-resistant bacterial infections
ATP 合酶作为针对耐药细菌感染的广谱抗菌药物临床前开发的新兴靶标
  • 批准号:
    472342
  • 财政年份:
    2022
  • 资助金额:
    $ 29.44万
  • 项目类别:
    Operating Grants
Clinical application of a rapid assay for antibacterial susceptibility test of beta-lactams and carbapenems antibacterial agents using MALDI-TOF MS
MALDI-TOF MS快速测定β-内酰胺类和碳青霉烯类抗菌药物药敏试验的临床应用
  • 批准号:
    22K07406
  • 财政年份:
    2022
  • 资助金额:
    $ 29.44万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Tailored and uniform fibre-like micelles as antibacterial agents.
定制且均匀的纤维状胶束作为抗菌剂。
  • 批准号:
    569719-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 29.44万
  • 项目类别:
    Postgraduate Scholarships - Doctoral
Development of pH-responsive carriers for the controlled release of encapsulated acidifying and antibacterial agents
开发用于控制释放封装酸化剂和抗菌剂的 pH 响应载体
  • 批准号:
    531450-2018
  • 财政年份:
    2022
  • 资助金额:
    $ 29.44万
  • 项目类别:
    Collaborative Research and Development Grants
Novel silver nanoparticles as antibacterial agents
作为抗菌剂的新型银纳米颗粒
  • 批准号:
    521908-2018
  • 财政年份:
    2021
  • 资助金额:
    $ 29.44万
  • 项目类别:
    Collaborative Research and Development Grants
Development of pH-responsive carriers for the controlled release of encapsulated acidifying and antibacterial agents
开发用于控制释放封装酸化剂和抗菌剂的 pH 响应载体
  • 批准号:
    531450-2018
  • 财政年份:
    2021
  • 资助金额:
    $ 29.44万
  • 项目类别:
    Collaborative Research and Development Grants
Novel silver nanoparticles as antibacterial agents
作为抗菌剂的新型银纳米颗粒
  • 批准号:
    521908-2018
  • 财政年份:
    2020
  • 资助金额:
    $ 29.44万
  • 项目类别:
    Collaborative Research and Development Grants
Development of pH-responsive carriers for the controlled release of encapsulated acidifying and antibacterial agents.
开发用于控制释放封装酸化剂和抗菌剂的 pH 响应载体。
  • 批准号:
    531450-2018
  • 财政年份:
    2020
  • 资助金额:
    $ 29.44万
  • 项目类别:
    Collaborative Research and Development Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了